{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Continuous Femoral Nerve Block Duration After Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to continue ropivacaine or switch to normal saline."
      },
      "Participants": {
        "score": 1,
        "evidence": "patients undergoing tricompartment total knee arthroplasty"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to continue ropivacaine or switch to normal saline."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated whether extending a continuous femoral nerve block (cFNB) to 4 days postoperatively enhances recovery compared to an overnight cFNB in patients undergoing tricompartment total knee arthroplasty."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were the time to achieve three discharge criteria (adequate analgesia, independence from intravenous analgesics, and ambulation of at least 30 m) and ambulatory distance in 6 minutes the afternoon after surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Twenty-five patients were randomised to each group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 4-day ropivacaine group met discharge criteria in a median of 25 hours (25th\u201375th percentiles: 21\u201347) compared to 71 hours (46\u201389) in the control group (estimated ratio, 0.47; 95% CI, 0.32\u20130.67; P < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported, with no differences in frequency or severity between groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov No. NCT00135889."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}